These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29932973)

  • 1. Combinatorial treatment of Rhizoma Paridis saponins and sorafenib overcomes the intolerance of sorafenib.
    Yao J; Man S; Dong H; Yang L; Ma L; Gao W
    J Steroid Biochem Mol Biol; 2018 Oct; 183():159-166. PubMed ID: 29932973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of metabonomics to identify serum biomarkers in murine H22 hepatocarcinoma and deduce antitumor mechanism of Rhizoma Paridis saponins.
    Qiu P; Man S; Yang H; Fan W; Yu P; Gao W
    Chem Biol Interact; 2016 Aug; 256():55-63. PubMed ID: 27369806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy of cyclophosphamide and Rhizoma Paridis Saponins on anti-hepatocarcinoma mice and effects on cytochrome p450 enzyme expression.
    Man S; Li Y; Fan W; Gao W; Liu Z; Zhang Y; Liu C
    Steroids; 2014 Feb; 80():1-6. PubMed ID: 24291418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcuma increasing antitumor effect of Rhizoma paridis saponins through absorptive enhancement of paridis saponins.
    Man S; Li Y; Fan W; Gao W; Liu Z; Li N; Zhang Y; Liu C
    Int J Pharm; 2013 Sep; 454(1):296-301. PubMed ID: 23850625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth inhibition by pennogenyl saponins from Rhizoma paridis on hepatoma xenografts in nude mice.
    Chen YS; He Y; Chen C; Zeng Y; Xue D; Wen FY; Wang L; Zhang H; Du JR
    Steroids; 2014 May; 83():39-44. PubMed ID: 24530287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcumin-enhanced antitumor effects of sorafenib via regulating the metabolism and tumor microenvironment.
    Man S; Yao J; Lv P; Liu Y; Yang L; Ma L
    Food Funct; 2020 Jul; 11(7):6422-6432. PubMed ID: 32613952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor and anti-metastatic mechanisms of Rhizoma paridis saponins in Lewis mice.
    Man S; Chai H; Cui J; Yao J; Ma L; Gao W
    Environ Toxicol; 2018 Feb; 33(2):149-155. PubMed ID: 29148169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Turmeric enhancing anti-tumor effect of Rhizoma paridis saponins by influencing their metabolic profiling in tumors of H22 hepatocarcinoma mice.
    Man S; Chai H; Qiu P; Liu Z; Fan W; Wang J; Gao W
    Pathol Res Pract; 2015 Dec; 211(12):948-54. PubMed ID: 26471217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
    Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
    Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
    Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
    Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor pathway of Rhizoma Paridis Saponins based on the metabolic regulatory network alterations in H22 hepatocarcinoma mice.
    Man S; Fan W; Liu Z; Gao W; Li Y; Zhang L; Liu C
    Steroids; 2014 Jun; 84():17-21. PubMed ID: 24642033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbiota-derived SSL6 enhances the sensitivity of hepatocellular carcinoma to sorafenib by down-regulating glycolysis.
    Zhang X; Wu L; Xu Y; Yu H; Chen Y; Zhao H; Lei J; Zhou Y; Zhang J; Wang J; Peng J; Jiang L; Sheng H; Li Y
    Cancer Lett; 2020 Jul; 481():32-44. PubMed ID: 32246956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
    Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
    J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.
    Lo J; Lau EY; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK
    Hepatology; 2015 Aug; 62(2):534-45. PubMed ID: 25902734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-fibrosis and anti-cirrhosis effects of Rhizoma paridis saponins on diethylnitrosamine induced rats.
    Man S; Fan W; Gao W; Li Y; Wang Y; Liu Z; Li H
    J Ethnopharmacol; 2014; 151(1):407-12. PubMed ID: 24212073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
    Kang D; Han Z; Oh GH; Joo Y; Choi HJ; Song JJ
    Yonsei Med J; 2017 Sep; 58(5):899-909. PubMed ID: 28792132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
    Dai N; Ye R; He Q; Guo P; Chen H; Zhang Q
    Oncol Rep; 2018 Dec; 40(6):3235-3248. PubMed ID: 30272354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.